Boston Scientific Shares Drop After CHAMPION-AF Data Shows Mixed Results for Watchman Implant
Boston Scientific shares fell about 9% after the CHAMPION-AF study of the Watchman FLX left atrial appendage closure device met its primary and secondary safety and efficacy endpoints but recorded a marginally higher ischemic stroke rate compared with non-vitamin K antagonist oral anticoagulants (NOACs). Analysts described the results as modest rat…